Loading stock data…
CSTL
$20.99+0.87 (+4.32%)
Market OpenUpdated 3:51 PM EDT
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Castle Biosciences, Inc. in the Healthcare sector is trading at $20.99. Wall Street consensus targets $44.00 (8 analysts), implying a +109.6% move over the next 12 months. The stock is currently 53% below its 52-week high of $44.28, remaining 27.0% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +109.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$20.99
Potential Downside
0%
Whystock Fair Value$20.99
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus8 analysts
Mean target$44.00+109.6%
Range$35.00 – $52.00
Fundamentals
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-2.78%
Volume
Today's trading volume
154,628
Recent News
How The Castle Biosciences (CSTL) Investment Story Is Evolving Without Fresh Analyst Commentary
The latest update on Castle Biosciences leaves the current price target unchanged, indicating that covering analysts have not adjusted their formal expectations at this time. With no new analyst commentary provided alongside this update, the story is being shaped more by the absence of fresh views than by new opinions. In the sections that follow, you will see how to track this kind of quiet period and what it might mean for staying on top of the evolving narrative around the stock. Analyst...
How The Castle Biosciences (CSTL) Story Is Shifting After Solid Q1 And Lower Targets
The modeled fair value estimate for Castle Biosciences has been trimmed from US$47.25 to US$45.88, a reduction of about 2.9% in the price target. That shift lines up with recent Street research, where solid Q1 execution is being weighed against more cautious assumptions on what investors should pay for the stock. As you read on, you will see how these updated targets fit into the evolving analyst narrative and what that might mean for your own view on the shares. Stay updated as the Fair...
Castle Biosciences, Inc. Q1 2026 Earnings Call Summary
Moby summary of Castle Biosciences, Inc.'s Q1 2026 earnings call
Castle Biosciences Q1 Earnings Call Highlights
Castle Biosciences (NASDAQ:CSTL) reported first-quarter 2026 revenue of $83.7 million, supported by continued growth in what management described as its “core revenue drivers,” DecisionDx-Melanoma and TissueCypher. Founder, President and CEO Derek Maetzold said test report volumes for the company’s
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Beats Revenue Estimates
Castle Biosciences (CSTL) delivered earnings and revenue surprises of +12.50% and +2.65%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?